Cargando…

Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy

SUMMARY: Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma, in whom AN manifested after the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Jenny S W, McCormack, Chris, Goh, Michelle, Chiang, Cherie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175602/
https://www.ncbi.nlm.nih.gov/pubmed/35642678
http://dx.doi.org/10.1530/EDM-21-0150
_version_ 1784722488590073856
author Yun, Jenny S W
McCormack, Chris
Goh, Michelle
Chiang, Cherie
author_facet Yun, Jenny S W
McCormack, Chris
Goh, Michelle
Chiang, Cherie
author_sort Yun, Jenny S W
collection PubMed
description SUMMARY: Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma, in whom AN manifested after the first cycle of peptide receptor radionuclide therapy (PRRT). A 40-year-old man was diagnosed with metastatic insulinoma after 5 months of symptomatic hypoglycemia. Within 1 month post PRRT, the patient became euglycemic but developed a pigmented, pruritic rash which was confirmed on biopsy as AN. We discuss the rare manifestation of AN in subjects with insulinoma, the role of insulin in the pathogenesis of AN, malignant AN in non-insulin-secreting malignancies and association with other insulin-resistant endocrinopathies such as acromegaly. LEARNING POINTS: Acanthosis nigricans (AN) is a common dermatosis which is typically asymptomatic and associated with the hyperinsulinemic state. Malignant AN can rapidly spread, cause pruritus and affect mucosa and the oral cavity. AN is extremely rare in patients with insulinoma despite marked hyperinsulinemia. Peptide receptor radionuclide therapy might have triggered TGF-α secretion in this subject which led to malignant AN. Rapid spread or unusual distribution of pruritic AN warrants further investigation to exclude underlying malignancy.
format Online
Article
Text
id pubmed-9175602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-91756022022-06-14 Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy Yun, Jenny S W McCormack, Chris Goh, Michelle Chiang, Cherie Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma, in whom AN manifested after the first cycle of peptide receptor radionuclide therapy (PRRT). A 40-year-old man was diagnosed with metastatic insulinoma after 5 months of symptomatic hypoglycemia. Within 1 month post PRRT, the patient became euglycemic but developed a pigmented, pruritic rash which was confirmed on biopsy as AN. We discuss the rare manifestation of AN in subjects with insulinoma, the role of insulin in the pathogenesis of AN, malignant AN in non-insulin-secreting malignancies and association with other insulin-resistant endocrinopathies such as acromegaly. LEARNING POINTS: Acanthosis nigricans (AN) is a common dermatosis which is typically asymptomatic and associated with the hyperinsulinemic state. Malignant AN can rapidly spread, cause pruritus and affect mucosa and the oral cavity. AN is extremely rare in patients with insulinoma despite marked hyperinsulinemia. Peptide receptor radionuclide therapy might have triggered TGF-α secretion in this subject which led to malignant AN. Rapid spread or unusual distribution of pruritic AN warrants further investigation to exclude underlying malignancy. Bioscientifica Ltd 2022-05-11 /pmc/articles/PMC9175602/ /pubmed/35642678 http://dx.doi.org/10.1530/EDM-21-0150 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unique/Unexpected Symptoms or Presentations of a Disease
Yun, Jenny S W
McCormack, Chris
Goh, Michelle
Chiang, Cherie
Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title_full Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title_fullStr Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title_full_unstemmed Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title_short Acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
title_sort acanthosis nigricans in a patient with metastatic insulinoma post peptide receptor radionuclide therapy
topic Unique/Unexpected Symptoms or Presentations of a Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175602/
https://www.ncbi.nlm.nih.gov/pubmed/35642678
http://dx.doi.org/10.1530/EDM-21-0150
work_keys_str_mv AT yunjennysw acanthosisnigricansinapatientwithmetastaticinsulinomapostpeptidereceptorradionuclidetherapy
AT mccormackchris acanthosisnigricansinapatientwithmetastaticinsulinomapostpeptidereceptorradionuclidetherapy
AT gohmichelle acanthosisnigricansinapatientwithmetastaticinsulinomapostpeptidereceptorradionuclidetherapy
AT chiangcherie acanthosisnigricansinapatientwithmetastaticinsulinomapostpeptidereceptorradionuclidetherapy